TMCnet News
Research and Markets: Global Hypercholesterolemia Market 2014-2018 With AbbVie, Astrazeneca, Merck & Co. & Pfizer DominatingDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/g4w2k7/global) has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to 2018 This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The Hypercholesteroemia market is associated with fierce competition among the market vendors for innovator drugs and generic manufacturers. The existing competition is expected to rise in the forecast period owing to the launch of generic versions for drugs that are set to lose their patent protection in the near-term. For instance, the 2013 fourth quarter sales for Crestor declined in Canada and Australia owing to the loss of exclusivity in these territories. Further, the drug is expected to face an additional decrease in sales as the US patent for the drug candidate is set to expire in 2016, while in the EU and Japan the patent will expire in 2017. In November 2011, Lipitor lost its exclusivity in the US market. Following the entry of its generic versions in May 2012, the US sales of Lipitor decreased by 81 percent in 2012 as compared to the 2011 US sales. According to the report, one of the main drivers in the market is the increasing risk of cardiovascular diseases. Hypercholesterolemia is one of the underlying causes for CVDs. WHO reported that in men aged 40 years, a 10 percent decrease in serum cholesterol levels is associated with a 50 percent reduction in heart disease within 5 years. Hence, risk management for CVDs also involves the reduction of hypercholesterolemia. Key Vendors
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/g4w2k7/global
|
